# Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base

> **NCT07145931** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 24 (estimated)

## Conditions studied

- Head and Neck Cancer Squamous Cell Carcinoma
- Skull Base--Cancer
- Neoadjuvant Chemoimmunotherapy
- Objective Response Rate

## Interventions

- **PROCEDURE:** Neoadjuvant chemoimmunotherapy
- **DRUG:** Tislelizumab Nab paclitaxel

## Key facts

- **NCT ID:** NCT07145931
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-20
- **Primary completion:** 2027-09-20
- **Final completion:** 2029-09-20
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07145931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07145931, "Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07145931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*